Palmoplantar exacerbation of psoriasis after nivolumab for lung cancer
Accepted for publication January 27, 2016
Correspondence Tracey Liebman, MD; Tracey.Liebman@nyumc.org
Disclosures The authors report no disclosures/conflicts of interest.
JCSO 2017;15(2):106-108
©2017 Frontline Medical Communications
doi https://doi.org/10.12788/jcso.0262
Additional studies are needed to more clearly characterize the specific cutaneous toxicities of nivolumab and to determine if particular skin reactions may indicate a better response to the anticancer agent. Side effects such as psoriasis can often be managed with topical therapies and may not require withdrawal of the medication. We encourage the collaboration of dermatologists and oncologists to enhance the diagnosis and management of these cutaneous side effects in cancer patients.
,false
